

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-087 / S-010

21-246 / S-007

ADMINISTRATIVE DOCUMENTS

AND

CORRESPONDENCE

Division of Antiviral Drug Products

REGULATORY PROJECT MANAGER REVIEW: Final Printed Labeling

- Application Numbers:** NDA 21-087/SLR-016
NDA 21-246/SLR-010
- Name of Drug:** Tamiflu® (oseltamivir phosphate) capsules and dry powder for suspension.
- Date submitted:** July 22, 2004, August 25, 2004 (amendment)
Date received: July 27, 2004, August 30, 2004 (amendment)
Date completed: September 3, 2004
- Applicant:** Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley, NJ 07110
- Materials Reviewed:**
1. July 25, 2004 and August 30, 2004 Final Printed Labeling (FPL), including:
 - Package Insert
 - Patient Package Insert
 2. June 23, 2004 approval letter and approved draft labeling

Background:

These supplemental new drug applications approved June 23, 2004 provided for revisions to the **Animal Toxicology, Precautions, Dosage and Administration**, and **Microbiology** sections of the package insert. In addition, revisions were made to the **Who should not take TAMIFLU?** section of the patient package insert.

The FPL was submitted July 22, 2004. Review of the labeling identified an error in the Patient Package Insert as described below. The Sponsor submitted an amendment to the FPL on August 25, 2004 containing corrected labeling.

Review Summary:

This FPL (including the package insert and patient package insert) is identical to the labeling included in the June 23, 2004 approval letter for these supplements, with the following exceptions:

Package Insert

In the **MICROBIOLOGY: Resistance** section, the following agreed upon changes were inadvertently omitted from the June 23, 2004 approval letter labeling. These minor corrections have been incorporated into the FPL:

“In clinical studies in the treatment of naturally acquired infection with influenza virus, 1.3% (4/301) of posttreatment isolates in adult patients and adolescents, and 8.6% (9/105) in pediatric patients aged 1 to 12 years showed emergence of influenza variants with decreased neuraminidase susceptibility in vitro to oseltamivir carboxylate.”



In the **PRECAUTIONS: General** section, the following minor editorial changes have been made:

“Use of TAMIFLU should not affect the evaluation of individuals for annual influenza vaccination in accordance with guidelines of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices.”

In the patient package insert, **What is TAMIFLU?** section, the second sentence incorrectly read ~~“TAMIFLU can also reduce the chance of getting the flu in people age 13 and older...”~~. The sentence now correctly reads “TAMIFLU can also reduce the chance of getting the flu in people age 13 and older...”.

Conclusions

This FPL, submitted July 22, 2004 is acceptable and an acknowledge and retain letter will be sent to the applicant.

Jeff D. O'Neill, ACRN
Regulatory Health Project Manager

Supervisory Comment/Concurrence:

Virginia Behr
Chief, Project Management Staff

Attachments: Package Insert and Patient Package Insert

WITHHOLD 18, PAGE(S)

Draft Labeling

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Jeff ONeill
9/7/04 02:00:04 PM
CSO

CSO review for Tamiflu FPL 21087-S016 & 21246-S010. Hard
copy sign-off 9/6/04

Virginia Behr
9/7/04 02:05:38 PM
CSO



NDA 21-087
NDA 21-246

Hoffmann-La Roche, Inc.
Attention: Lynn DeVenezia-Tobias
Program Manager
Drug Regulatory Affairs
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Ms. DeVenezia-Tobias:

We acknowledge receipt of your July 22, 2004 submission containing final printed labeling in response to our June 23, 2004 letter approving your supplemental new drug applications for Tamiflu (oseltamivir phosphate) capsules and dry powder for suspension. We also acknowledge receipt of your August 25, 2004 submission containing amended final printed labeling.

We have reviewed the labeling that you submitted in accordance with our June 23, 2004 letter, and we find it acceptable.

If you have any questions, call Jeff D. O'Neill, Regulatory Health Project Manager, at (301) 827-2335.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosures

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Debra Birnkrant
9/14/04 01:16:12 PM
NDA 21-246, 21-087